|
POT1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.33066907387547E-16 |
| Normal-vs-Stage2 |
2.1365000000273E-06 |
| Normal-vs-Stage3 |
5.21915843876286E-13 |
| Normal-vs-Stage4 |
4.41749969937177E-11 |
| Stage1-vs-Stage2 |
2.964400E-01 |
| Stage1-vs-Stage3 |
4.112800E-01 |
| Stage1-vs-Stage4 |
2.883800E-01 |
| Stage2-vs-Stage3 |
1.635830E-01 |
| Stage2-vs-Stage4 |
1.272170E-01 |
| Stage3-vs-Stage4 |
7.065000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.848870E-04 |
| Normal-vs-Asian |
8.32419688734376E-11 |
| Caucasian-vs-AfricanAmerican |
2.252000E-01 |
| Caucasian-vs-Asian |
6.657800E-01 |
| AfricanAmerican-vs-Asian |
1.704000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.12132525487141E-14 |
| Normal-vs-Female |
1.62614366416847E-12 |
| Male-vs-Female |
2.696000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.63091762317435E-12 |
| Normal-vs-Age(41-60Yrs) |
1.54765089632747E-13 |
| Normal-vs-Age(61-80Yrs) |
6.0022986581032E-11 |
| Normal-vs-Age(81-100Yrs) |
1.817900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.738600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.953800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.914600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.871600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.377200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.346800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.133650E-01 |
| Classical-VS-Follicular |
1.738610E-01 |
| Classical-VS-Other |
3.723200E-01 |
| Classical-VS-Normal |
1.42500011790503E-10 |
| Tall-VS-Follicular |
2.103900E-02 |
| Tall-VS-Other |
9.383600E-01 |
| Tall-VS-Normal |
2.71019984232623E-10 |
| Follicular-VS-Other |
2.884800E-01 |
| Follicular-VS-Normal |
8.1657999995155E-07 |
| Other-VS-Normal |
8.799200E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.35997937542743E-14 |
| Normal-vs-N1 |
8.86402062860725E-13 |
| N0-vs-N1 |
4.210200E-02 |
|
|
